| Literature DB >> 33289696 |
Lasse Oinonen1, Antti Tikkakoski1,2, Jenni Koskela1,3, Arttu Eräranta1, Mika Kähönen1,2, Onni Niemelä4, Jukka Mustonen1,3, Ilkka Pörsti1,3.
Abstract
Parathyroid hormone has been related with the risk of hypertension, but the matter remains controversial. We examined the association of parathyroid hormone with central blood pressure and its determinants in 622 normotensive or never-treated hypertensive subjects aged 19-72 years without diabetes, cardiovascular or renal disease, or cardiovascular medications. The methods were whole-body impedance cardiography and analyses of pulse wave and heart rate variability. Cardiovascular function was examined in sex-specific tertiles of plasma parathyroid hormone (mean concentrations 3.0, 4.3 and 6.5 pmol/L, respectively) during head-up tilt. Explanatory factors for haemodynamics were further investigated using linear regression analyses. Mean age was 45.0 (s.d. 11.7) years, BMI 26.8 (4.4) kg/m2, seated office blood pressure 141/90 (21/12) mmHg, and 309 subjects (49.7%) were male. Only five participants had elevated plasma parathyroid hormone and calcium concentrations. Highest tertile of parathyroid hormone presented with higher supine and upright aortic diastolic blood pressure (P < 0.01) and augmentation index (P < 0.01), and higher upright systemic vascular resistance (P < 0.05) than the lowest tertile. The tertiles did not present with differences in pulse wave velocity, cardiac output, or measures of heart rate variability. In linear regression analyses, parathyroid hormone was an independent explanatory factor for aortic systolic (P = 0.005) and diastolic (P = 0.002) blood pressure, augmentation index (P = 0.002), and systemic vascular resistance (P = 0.031). To conclude, parathyroid hormone was directly related to central blood pressure, wave reflection, and systemic vascular resistance in subjects without cardiovascular comorbidities and medications. Thus, parathyroid hormone may play a role in the pathophysiology of primary hypertension.Entities:
Keywords: augmentation index; blood pressure; parathyroid hormone; vascular resistance
Year: 2021 PMID: 33289696 PMCID: PMC7923049 DOI: 10.1530/EC-20-0446
Source DB: PubMed Journal: Endocr Connect ISSN: 2049-3614 Impact factor: 3.335
Demographics, clinical characteristics and laboratory results in tertiles of plasma parathyroid hormone concentration adjusted for sex.
| Demographics and clinical characteristics | PTH tertile 1 ( | PTH tertile 2 ( | PTH tertile 3 ( |
|---|---|---|---|
| Males (%) | 49.5 | 50 | 49.5 |
| Age (years) | 42.3 (12.7) | 45.8 (10.8)a | 47.0 (11.2)a |
| BMI (kg/m2) | 25.4 (3.9) | 27.1 (4.1)a | 27.9 (4.7)a |
| Extracellular water volume (L) | 12.9 (1.9) | 12.9 (1.8) | 13.0 (1.8) |
| Extracellular water balance | 1.00 (0.12) | 0.99 (0.10) | 0.98 (0.10) |
| Current smokers (%) | 15.5 | 12 | 10.6 |
| Alcohol consumption (standard drinks/week) | 5.0 (6.6) | 4.5 (5.3) | 4.2 (5.5) |
| Dairy product consumption (standard dose/day) | 3.5 (2.3) | 3.1 (2.0) | 2.8 (1.9)a |
| Calcium supplement users (%) | 1.9 | 3.8 | 3.8 |
| Vitamin D supplement users (%) | 18.9 | 15.9 | 13.9 |
| Seated brachial office blood pressure measured by physician (mmHg) | 136 (21)/86 (11) | 143 (20)a/90 (12)a | 144 (20)a/93 (12)a,b |
| Supine brachial blood pressure measured by nurse (mmHg) | 127 (17)/78 (11) | 134 (18)a/81 (12)a | 136 (19)a/84 (12)a |
| Supine radial laboratory blood pressure (mmHg) | 127 (19)/72 (12) | 132 (19)a/76 (12)a | 135 (20)a/79 (13)a |
Results shown as mean (s.d.).
aP < 0.05 vs tertile 1; bP < 0.05 vs tertile 2.
Fasting blood and plasma biochemistry results in tertiles of plasma parathyroid hormone concentration adjusted for sex.
| PTH tertile 1 ( | PTH tertile 2 ( | PTH tertile 3 ( | |
|---|---|---|---|
| PTH (pmol/L) | 3.0 (3.0–3.1) | 4.3 (4.2–4.3)a | 6.5 (6.3–6.8)a,b |
| Calcium (mmol/L) | 2.3 (2.3–2.3) | 2.3 (2.3–2.3) | 2.3 (2.3–2.3) |
| Phosphate (mmol/L) | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 0.9 (0.9–0.9)a,b |
| 25(OH)D3 (nmol/L) | 82 (76–88) | 70 (65–75)a | 63 (59–67)a |
| 1,25(OH)2D3 (pmol/L) | 107 (102–112) | 108 (103–113) | 110 (105–115) |
| Haemoglobin (g/L) | 144 (142–146) | 144 (143–146) | 145 (143–146) |
| C-reactive protein (mg/L) | 1.6 (1.2–2.2) | 1.6 (1.3–1.8) | 1.8 (1.5–2.2) |
| Creatinine (μmol/L) | 74 (73–76) | 73 (72–75) | 74 (72–76) |
| Cystatin C (mg/L) | 0.8 (0.8–0.8) | 0.9 (0.8–0.9)a | 0.9 (0.8–0.9)a |
| Uric acid (μmol/L) | 290 (280–300) | 307 (297–317) | 313 (302–325)a |
| ALT (U/L) | 27 (25–29) | 30 (27–33) | 33 (30–37)a |
| ALP (U/L) | 58 (56–60) | 60 (58–63) | 66 (64–69)a,b |
| Sodium (mmol/L) | 140 (140–1416) | 140 (140–141) | 141 (140–141) |
| Potassium (mmol/L) | 3.8 (3.8–3.9) | 3.8 (3.8–3.9) | 3.8 (3.7–3.8) |
| Renin (ng Ang I/mL/h) | 1.0 (0.9–1.1) | 1.0 (0.8–1.1) | 1.0 (0.8–1.1) |
| Aldosterone (pmol/L) | 518 (470–567) | 493 (458–528) | 519 (449–588) |
| Total cholesterol (mmol/L) | 5.0 (4.8–5.1) | 5.2 (5.1–5.4)a | 5.3 (5.1–5.4)a |
| Triglycerides (mmol/L) | 1.2 (1.0–1.3) | 1.2 (1.2–1.3) | 1.4 (1.2–1.6)a |
| HDL cholesterol (mmol/L) | 1.6 (1.6–1.7) | 1.6 (1.5–1.7) | 1.5 (1.5–1.6) |
| LDL cholesterol (mmol/L) | 2.9 (2.7–3.0) | 3.1 (3.0–3.2)a | 3.2 (3.1–3.3)a |
| Glucose (mmol/L) | 5.3 (5.3–5.4) | 5.5 (5.4–5.6)a | 5.5 (5.5–5.6)a |
| Insulin (mU/L) | 7.5 (7.8–8.3) | 8.2 (7.3–9.0) | 11.4 (7.5–15.2) |
| Estimated GFR (mL/min/1.73 m2) | 103 (100–105) | 97 (95–100)a | 96 (94–99)a |
| QUICKI | 0.365 (0.356– 0.374) | 0.354 (0.349–0.359) | 0.349 (0.342–0.356)a |
Results shown as mean (95% CI of the mean). Due to missing values, all blood and plasma biochemistry results were available in tertile 1 for 197 subjects, in tertile 2 for 194 subjects, and in tertile 3 for 186 subjects.
aP < 0.05 vs tertile 1; bP < 0.05 vs tertile 2.
1,25(OH)2D3, 1,25-dihydroxyvitamin D3; 25(OH)D3, 25-hydroxyvitamin D3; ALP, alkaline phosphatase; ALT, alanine aminotransferase; GFR, glomerular filtration rate (estimated by cystatin C based CKD-EPI formula); HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone; QUICKI, quantitative insulin sensitivity check index.
Figure 1Aortic systolic blood pressure (A), diastolic blood pressure (B), augmentation index adjusted to heart rate of 75 b.p.m. (C), and pulse wave velocity (D) in tertiles of plasma parathyroid hormone concentration adjusted for sex; mean (circle) with s.e.m. (whiskers), multivariable ANOVA for repeated measures with the Bonferroni correction. The covariates were age, body mass index, quantitative insulin sensitivity check index, dairy product consumption, estimated glomerular filtration rate, and plasma concentrations of phosphate, 25-hydroxyvitamin D3, uric acid, alanine aminotransferase, alkaline phosphatase, low-density lipoprotein cholesterol, and triglycerides. **P < 0.01 tertile 3 vs tertile 1 during the 10 min of recording.
Figure 2Heart rate (A), cardiac output (B), and systemic vascular resistance (C) in tertiles of plasma parathyroid hormone concentration adjusted for sex; mean (circle) with s.e.m. (whiskers), multivariable ANOVA for repeated measures with the Bonferroni correction. Covariates as in Fig. 1. *P < 0.05, tertile 3 vs. tertile 1 during the 10 min of recording.
Figure 3Heart rate variability in supine (solid boxes) and upright (striped boxes) positions: high-frequency power (A), low-frequency power (B), and low-frequency – high-frequency ratio (C) in tertiles of plasma parathyroid hormone concentration adjusted for sex; median (thick line inside box), 25th to 75th percentile (box), and range (whiskers, outliers omitted).
Significant explanatory variables for aortic systolic and diastolic blood pressures, augmentation index (adjusted to heart rate of 75 b.p.m.), and systemic vascular resistance in linear regression analysis.
| Aortic systolic blood pressure | B | Beta | Aortic diastolic blood pressure | B | Beta | ||
|---|---|---|---|---|---|---|---|
| Model (R2 = 0.400) | Model (R2 = 0.391) | ||||||
| (constant) | −0.545 | (constant) | 28.046 | ||||
| PWV | 2.969 | 0.315 | <0.001 | PWV | 1.984 | 0.31 | <0.001 |
| Estimated GFR | −0.163 | 0.163 | <0.001 | Estimated GFR | −0.114 | −0.168 | 0.001 |
| Calcium | 26.461 | 0.16 | <0.001 | Calcium | 15.944 | 0.143 | 0.001 |
| BMI | 0.604 | 0.146 | 0.001 | LDL cholesterol | 1.716 | 0.134 | 0.004 |
| LDL | 2.295 | 0.121 | 0.007 | Age | −0.135 | −0.129 | 0.021 |
| PTH (Lg10) | 14.249 | 0.12 | 0.003 | PTH (Lg10) | 9.573 | 0.119 | 0.005 |
| ECW balance | 14.315 | 0.082 | 0.037 | Phosphate | −7.79 | −0.106 | 0.014 |
| BMI | 0.286 | 0.103 | 0.022 | ||||
| Alcohol, drinks per week (Lg10) | 2.865 | 0.1 | 0.012 | ||||
| Model (R2= 0.567) | Model (R2 = 0.264) | ||||||
| (constant) | −17.264 | (constant) | 44.021 | ||||
| Age | 0.521 | 0.553 | <0.001 | Sex (male) | −201.93 | −0.324 | <0.001 |
| Sex (male) | −9.91 | −0.449 | <0.001 | Age | 6.251 | 0.235 | <0.001 |
| Smoking (present) | 3.949 | 0.119 | 0.001 | Calcium | 382.502 | 0.134 | 0.002 |
| PTH (Lg10) | 8.114 | 0.112 | 0.002 | ECW balance | 354.311 | 0.118 | 0.009 |
| LDL cholesterol | 0.883 | 0.076 | 0.045 | Smoking (previous) | 73.793 | 0.109 | 0.013 |
| CRP (Lg10) | 2.014 | 0.072 | 0.044 | PTH (Lg10) | 199.785 | 0.098 | 0.031 |
| Vitamin D supplement use | 73.631 | 0.087 | 0.042 |
Variables in Model: age, sex, BMI, estimated GFR (CKD-EPI-Cystatin C), ECW balance, Lg10 of alcohol consumption, Lg10 of dairy product consumption, smoking status, vitamin D supplement use, Lg10 of fasting plasma glucose, Lg10 of fasting plasma insulin, Lg10 of C-reactive protein, Lg10 of PTH, calcium, phosphate, Lg10 of 25(OH)D3, sodium, uric acid, Lg10 of alkaline phosphatase, Lg10 of alanine aminotransferase, LDL cholesterol, HDL cholesterol, Lg10 of triglycerides, Lg10 of renin, Lg10 of aldosterone, and PWV (PWV not for systemic vascular resistance).
CRP, C-reactive protein; ECW, extra-cellular water; GFR, glomerular filtration rate; LDL, low-density lipoprotein; PTH, parathyroid hormone; PWV, pulse wave velocity.